IL315471A - Use of isatuximab in combination with other agents to treat multiple myeloma - Google Patents

Use of isatuximab in combination with other agents to treat multiple myeloma

Info

Publication number
IL315471A
IL315471A IL315471A IL31547124A IL315471A IL 315471 A IL315471 A IL 315471A IL 315471 A IL315471 A IL 315471A IL 31547124 A IL31547124 A IL 31547124A IL 315471 A IL315471 A IL 315471A
Authority
IL
Israel
Prior art keywords
isatuximab
agents
treatment
combination
multiple myeloma
Prior art date
Application number
IL315471A
Other languages
English (en)
Hebrew (he)
Original Assignee
Sanofi Aventis Us Llc
Blondel Marielle Chiron
Desjonqueres Alexandre
Klippel Zandra Karina
Meloni Marco
Virone Oddos Angela
Sanofi Aventis Rech & D?Veloppement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Us Llc, Blondel Marielle Chiron, Desjonqueres Alexandre, Klippel Zandra Karina, Meloni Marco, Virone Oddos Angela, Sanofi Aventis Rech & D?Veloppement filed Critical Sanofi Aventis Us Llc
Publication of IL315471A publication Critical patent/IL315471A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL315471A 2022-03-07 2023-03-07 Use of isatuximab in combination with other agents to treat multiple myeloma IL315471A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263317253P 2022-03-07 2022-03-07
PCT/US2023/063869 WO2023172917A1 (en) 2022-03-07 2023-03-07 Use of isatuximab in combination with other agents for the treatment of multiple myeloma

Publications (1)

Publication Number Publication Date
IL315471A true IL315471A (en) 2024-11-01

Family

ID=85800365

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315471A IL315471A (en) 2022-03-07 2023-03-07 Use of isatuximab in combination with other agents to treat multiple myeloma

Country Status (10)

Country Link
US (1) US20250177519A1 (enExample)
EP (1) EP4489766A1 (enExample)
JP (1) JP2025509343A (enExample)
KR (1) KR20250029015A (enExample)
CN (1) CN119486744A (enExample)
AU (1) AU2023231217A1 (enExample)
CA (1) CA3245572A1 (enExample)
IL (1) IL315471A (enExample)
MX (1) MX2024010925A (enExample)
WO (1) WO2023172917A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913777XA (en) 2013-03-13 2020-03-30 Sanofi Sa Compositions comprising anti-cd38 antibodies and carfilzomib

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP3154581B1 (en) * 2014-06-16 2019-02-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Blocking cd38 using anti-cd38 f(ab')2 to protect nk cells
US11221328B2 (en) * 2017-03-08 2022-01-11 Nantcell, Inc. Hypoxic NK cells and methods therefor
MA54952A (fr) 2019-02-06 2022-05-11 Synthorx Inc Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
CN114867485A (zh) 2019-10-31 2022-08-05 全国儿童医院研究所 Cd38敲除的原代和扩增的人nk细胞的生成
PH12023550160A1 (en) * 2020-07-31 2023-09-18 Exelixis Inc Combinations for the Treatment of Cancer

Also Published As

Publication number Publication date
KR20250029015A (ko) 2025-03-04
EP4489766A1 (en) 2025-01-15
CA3245572A1 (en) 2023-09-14
JP2025509343A (ja) 2025-04-11
AU2023231217A1 (en) 2024-10-17
CN119486744A (zh) 2025-02-18
US20250177519A1 (en) 2025-06-05
MX2024010925A (es) 2025-02-10
WO2023172917A1 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
IL284671A (en) Antiproliferative compounds and active denaturing agents for use in the treatment of multiple myeloma
IL290415A (en) Compounds with deuterium for use in cancer treatment
IL297849B1 (en) Composition for use in the treatment of APOL1-related disease
GB201820450D0 (en) Compound and its use for the treatment of alpha1-antitryspin deficiency
SMT202600134T1 (it) Lumateperone per uso nel trattamento della schizofrenia
IL292181B1 (en) Anti-CD19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
ZA202207493B (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
IL278895A (en) Diltiazem for use in the treatment of microbial infections
GB201918404D0 (en) Compounds and their use for the treatment of aplha1-antitrypsin deficiency
GB201918413D0 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB201918414D0 (en) Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
IL309172A (en) Vulbanazine for use in the additional treatment of schizophrenia
IL282718A (en) Compounds for use in the treatment or prevention of pain, inflammation and/or autoimmune diseases
GB202002299D0 (en) Agents for use in the treatment of tissue damage
PL3911347T3 (pl) Kompozycja do stosowania w leczeniu nietrzymania moczu u kobiet
IL288307A (en) Preparations for use in the treatment of insulin deficiency conditions
GB201918416D0 (en) Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
GB202014589D0 (en) Agents for use in the treatment of amyloidosis
GB202302121D0 (en) Compounds for use in the treatment of schizophrenia
AU2023902805A0 (en) Combination for use in the treatment of glioma
GB201918539D0 (en) Compounds for use in treatment and prophylaxis
HK40088920A (en) Methylthioninium compounds for use in the treatment of covid-19
HK40087864A (en) Methylthioninium compounds for use in the treatment of covid-19